Skip to main content

Peer Review reports

From: The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors

Original Submission
16 Jul 2020 Submitted Original manuscript
24 Sep 2020 Author responded Author comments - Zahra Karimian
4 Aug 2020 Reviewed Reviewer Report
22 Aug 2020 Reviewed Reviewer Report
Resubmission - Version 2
24 Sep 2020 Submitted Manuscript version 2
7 Oct 2020 Author responded Author comments - Zahra Karimian
Resubmission - Version 3
7 Oct 2020 Submitted Manuscript version 3
Publishing
9 Oct 2020 Editorially accepted
23 Nov 2020 Article published 10.1186/s12885-020-07518-5

You can find further information about peer review here.

Back to article page
\